Skip to main content
. 2021 Aug 18;12(2):907–923. doi: 10.1016/j.apsb.2021.08.016

Figure 6.

Figure 6

In vivo bio-distribution and anti-metastasis activities of TFENs based on lung metastasis model of breast cancer. (A) In vivo bio-distribution of DiR-loaded TFENs in heart, liver, spleen, lung, and kidney at different time points (6, 12, 24, 48, and 72 h). (B) Relative body weight variations over 9 days after the treatment of TFENs via i.v. injection and oral route. (C) Total numbers of metastatic tumor nodules and (D) lung metastasis inhibition profiles of TFENs at the end of experiments. (E) Representative images and H&E staining of the lungs from different treatment groups on day 19 (scale bar = 100 mm). Microbiome analysis of the fecal samples. (f) α-Diversities were presented by box plot of the Simpson indexes. (G) Principle component analysis (PCA) plots of gut microbiota. (H) Gut microbiota compositions in different treatment groups at the genus level. (I–L) Relative abundances of the typical beneficial bacteria and harmful bacteria in different treatment groups. (M) Survival rates for each group receiving different treatments. Each point represents the mean ± SEM (n = 8). ∗P < 0.05, ∗∗P < 0.01. ns, no significance.